Close Menu

BGI

MGI hopes to ship the sequencer, one of several products it unveiled at the International Conference on Genomics, to early-access partners in early 2020.

The company claims that certain Illumina sequencers infringe its US Patent No. 9,944,984, "Methods and Compositions for Efficient Base Calling in Sequencing Reactions."

Among other projects, the partners plan to establish a large-scale tropical plant genomics R&D center and associated sequencing and bioinformatics infrastructure.

The suits, targeting products that include the BGISEQ-500 and MGISEQ-2000 platforms, add fuel to the ongoing patent dispute between the two firms.

Under the partnership, Heidelberg-based Eluthia will become the primary distributor of BGI's NIFTY noninvasive prenatal test in Germany.

Scientists from the UK and China discussed two new NIPTs that include single-gene disorders and a study to estimate disease recurrence risk in families.

Last year, the firm saw 21 percent growth in reproductive health, 56 percent growth in oncology, and 49 percent growth in infectious disease testing.

Two senators have asked a government watchdog to see if CMS made payments to US providers who have partnered with firms including WuXi NextCode and BGI.

The complaint, filed yesterday, alleges that Illumina's two-channel sequencing systems infringe Complete Genomics' US Patent No. 9,222,132.

The lawsuit follows a similar one that Illumina filed earlier this year in Germany against Latvia MGI Tech, another subsidiary of BGI Group.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.